Enlivex Therapeutics Ltd. — FY2021 Form 20-F
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing; separate Q4 results are not provided. Financial statements are prepared under U.S. GAAP. Enlivex is an Israel-based clinical-stage biotechnology company developing Allocetra, an investigational cell therapy targeting sepsis and solid tumors. Its ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange as ENLV.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.9 million | $6.1 million |
| General and administrative expense | $6.4 million | $3.7 million |
| Operating loss | $19.3 million | $9.8 million |
| Other income (expense), net | $4.8 million income | $2.0 million expense |
| Net loss | $14.5 million | $11.8 million |
| Net loss per share, basic and diluted | $0.81 | $0.90 |
| Net cash used in operating activities | $17.5 million | $11.0 million |
At December 31, 2021, cash and cash equivalents were $11.2 million, short-term deposits $10.0 million, and marketable securities $62.9 million—approximately $84.1 million combined. Working capital was approximately $81.7 million; accumulated deficit was $52.0 million. Total liabilities were $10.1 million, including $6.0 million of operating lease liabilities. The filing does not report conventional borrowings as a material balance. No meaningful revenue-based margin can be calculated because the company has no revenue.
Net cash used in investing activities was $38.4 million, largely reflecting purchases of marketable securities net of sales and releases of deposits. Financing activities provided $61.0 million, including $53.2 million net proceeds from share and warrant issuance and $7.7 million from warrant exercises. FY2021 other income included $5.6 million of marketable-securities income, of which $4.6 million was unrealized; currency differences were a $0.6 million expense.
Changes versus prior year
- R&D expense increased 112% and G&A expense increased 73%, primarily due to more personnel and stock compensation, clinical and preclinical work, materials, director compensation, and insurance.
- Operating loss nearly doubled, while net loss increased 22%. The smaller net-loss increase reflected the swing from a $2.0 million net other expense in 2020 to $4.8 million net other income in 2021, mainly from investment gains and lower currency-related expenses.
- Operating cash use rose by $6.5 million. Cash provided by financing increased, principally due to the February 2021 offering and warrant exercises.
- The company changed Enlivex R&D’s functional currency from NIS to U.S. dollars effective September 30, 2021. It reported $124,000 of other comprehensive income in 2021, compared with $2.3 million in 2020.
Outlook, developments, and risks
- Funding: Management estimated existing resources would fund planned operations through Q3 2024; the financial-statement note also states resources should support development for at least 12 months after the April 2022 filing. The company expects continuing losses and needs substantial additional financing. It warns that without additional capital, there is substantial doubt about its ability to continue activities beyond Q3 2024. No committed external funding was disclosed.
- Sepsis: A randomized, placebo-controlled Phase II trial began in 2021 using liquid Allocetra in pneumonia-associated sepsis. The company planned to seek regulatory approval to use frozen formulation and broaden enrollment to other infection sources. The proposed amendments were expected to defer trial completion by approximately six to eight months. Earlier Phase Ib results were favorable but compared 10 treated patients with historical matched controls, not a randomized control group.
- Solid tumors: The company planned a Phase Ib combination trial with chemotherapy and a Phase I/II combination trial with a checkpoint inhibitor in late 2022. These were plans, not reported trial outcomes.
- COVID-19: The company deprioritized the program and planned to stop recruiting into its Phase IIb trial, reallocating resources to sepsis and oncology. Enrollment was insufficient for meaningful efficacy assessment; enrolled patients were to continue safety follow-up.
- Formulation and manufacturing: The company reported completing development of a frozen formulation in Q1 2022, ahead of schedule; its multi-year shelf life was an expectation, not an established commercial result. Construction of a new Israeli cGMP facility was expected to finish in Q4 2022, with estimated costs of approximately $11 million. Regulatory approval and successful manufacturing scale-up remain uncertain.
- Key risks and contingencies: Clinical failure or delay, regulatory and manufacturing hurdles, contamination or supply issues, competition, and the need for additional capital could materially impair prospects. The company had $7.8 million of contingent IIA grant repayment/royalty obligations; royalties generally apply to qualifying sales, and no royalties had been paid by year-end. IIA rules may restrict technology transfer or manufacturing outside Israel. Lease obligations totaled $7.0 million undiscounted. The filing reported no pending litigation expected to have a material adverse effect.
- Audits and controls: The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; no critical audit matters were identified. Management reported effective disclosure controls and internal controls as of year-end.
Important facts for investors to verify
- Current cash, investment portfolio composition and liquidity, subsequent cash burn, and whether the stated Q3 2024 runway remains achievable.
- Regulatory status, enrollment, timelines, endpoints, and results of the Phase II sepsis trial, including approval to use frozen formulation and expand infection sources.
- Whether planned solid-tumor trials began, and their actual protocols, funding, and progress.
- Progress, cost, regulatory readiness, and production capacity of the new cGMP facility; clarify the filing’s construction timeline and subsequent updates.
- Actual and potential dilution from outstanding options and warrants, future financing, and the Executive Chairman’s 3.33% commercial-transaction proceeds arrangement, subject to its stated terms and threshold.
- Potential U.S. PFIC status and related tax consequences; the filing says the company likely will be classified as a PFIC and does not intend to provide information required for a QEF election.